Your browser doesn't support javascript.
loading
An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review.
Shipman, William D; Vernice, Nicholas A; Demetres, Michelle; Jorizzo, Joseph L.
Afiliação
  • Shipman WD; Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional M.D.-Ph.D. Program, New York, New York; Department of Dermatology, Weill Cornell Medicine, New York, New York. Electronic address: wdshipman@gmail.com.
  • Vernice NA; Department of Dermatology, Weill Cornell Medicine, New York, New York.
  • Demetres M; Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medicine, New York, New York.
  • Jorizzo JL; Department of Dermatology, Weill Cornell Medicine, New York, New York; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
J Am Acad Dermatol ; 82(3): 709-722, 2020 Mar.
Article em En | MEDLINE | ID: mdl-31306730
BACKGROUND: Hydroxychloroquine is widely used for the treatment of cutaneous lupus erythematosus (CLE). Although new recommendations exist for hydroxychloroquine dosing, there is still uncertainty about the dosage that will elicit a satisfactory response in CLE while limiting adverse effects, specifically retinopathy. OBJECTIVE: To summarize hydroxychloroquine dosages, outcomes, and adverse effects in the treatment of CLE, focusing on retinopathy. METHODS: A comprehensive literature search from inception to December 2018 was performed in Ovid MEDLINE, Ovid Embase, and The Cochrane Library (Wiley). Studies were screened against predefined inclusion and exclusion criteria. RESULTS: Twelve studies were selected and included 5 retrospective studies, 3 prospective studies, 2 case series, and 2 randomized controlled trials. These studies show that a hydroxychloroquine dosage up to 400 mg/d is effective for most CLE patients (range of effectiveness, 50%-97%), with few adverse effects. One incidence of retinopathy, after a very high cumulative dose, was reported across all 12 studies (852 total patients). LIMITATIONS: Because retinopathy and other serious adverse effects may not appear until much later, many of these studies are limited by short follow-up time. CONCLUSIONS: This evidence suggests that hydroxychloroquine for CLE is effective at 400 mg/d, with an exceedingly low incidence of retinopathy and other adverse effects.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lúpus Eritematoso Cutâneo / Hidroxicloroquina Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lúpus Eritematoso Cutâneo / Hidroxicloroquina Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article